UA114502C2 - Вакцина mycoplasma hyopneumoniae - Google Patents

Вакцина mycoplasma hyopneumoniae

Info

Publication number
UA114502C2
UA114502C2 UAA201410837A UAA201410837A UA114502C2 UA 114502 C2 UA114502 C2 UA 114502C2 UA A201410837 A UAA201410837 A UA A201410837A UA A201410837 A UAA201410837 A UA A201410837A UA 114502 C2 UA114502 C2 UA 114502C2
Authority
UA
Ukraine
Prior art keywords
hyo
mycoplasma hyopneumoniae
preparation
hyopneumoniae vaccine
soluble part
Prior art date
Application number
UAA201410837A
Other languages
English (en)
Inventor
Джеффрі Е. Галвін
Грегорі П. Нітзель
Джон Кейт Гарретт
Джеймс Р. ІІ Кулауік
Трайсі Л. Рікер
Меган Маріе Смутзер
Original Assignee
Зоетіс Сервісіз Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48087777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA114502(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зоетіс Сервісіз Ллс filed Critical Зоетіс Сервісіз Ллс
Publication of UA114502C2 publication Critical patent/UA114502C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Винахід стосується імуногенної композиції та способу її одержання, що містить розчинну частину цільноклітинного препарату Mycoplasma hyopneumoniae (M.hyo), де розчинна частина препарату M.hyo містить M.hyo-специфічні розчинні антигени протеїну та є відокремленою від нерозчинного клітинного матеріалу та вільною як від (i) IgG, так і (ii) імунокомплексів, що складаються з антигену, приєднаного до імуноглобуліну.
UAA201410837A 2012-04-04 2013-04-03 Вакцина mycoplasma hyopneumoniae UA114502C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620165P 2012-04-04 2012-04-04
PCT/US2013/035083 WO2013152081A1 (en) 2012-04-04 2013-04-03 Mycoplasma hyopneumoniae vaccine

Publications (1)

Publication Number Publication Date
UA114502C2 true UA114502C2 (uk) 2017-06-26

Family

ID=48087777

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201410837A UA114502C2 (uk) 2012-04-04 2013-04-03 Вакцина mycoplasma hyopneumoniae

Country Status (32)

Country Link
US (5) US9120859B2 (uk)
EP (2) EP4039271A1 (uk)
JP (1) JP6271502B2 (uk)
KR (1) KR101747507B1 (uk)
CN (1) CN104271154B (uk)
AR (1) AR090611A1 (uk)
AU (1) AU2013243535C1 (uk)
BR (1) BR112014024533B1 (uk)
CA (1) CA2869603C (uk)
CL (1) CL2014002674A1 (uk)
CO (1) CO7160026A2 (uk)
CR (1) CR20140436A (uk)
CY (1) CY1124982T1 (uk)
DK (1) DK2833908T3 (uk)
ES (1) ES2905302T3 (uk)
GT (1) GT201400210A (uk)
HK (1) HK1207284A1 (uk)
HR (2) HRP20220175T1 (uk)
HU (1) HUE058321T2 (uk)
LT (1) LT2833908T (uk)
MX (2) MX336504B (uk)
MY (1) MY166792A (uk)
NI (1) NI201400117A (uk)
PH (1) PH12014502250A1 (uk)
PL (1) PL2833908T3 (uk)
PT (1) PT2833908T (uk)
RS (1) RS62881B1 (uk)
RU (1) RU2644254C2 (uk)
SI (1) SI2833908T1 (uk)
TW (1) TWI602575B (uk)
UA (1) UA114502C2 (uk)
WO (1) WO2013152081A1 (uk)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
DK2938356T3 (da) 2012-12-28 2020-07-27 Boehringer Ingelheim Vetmedica Gmbh Immunogen sammensætning som omfatter mycoplasma-antigener
CA2896298C (en) 2012-12-28 2024-01-16 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US9951109B2 (en) * 2013-11-21 2018-04-24 Agricultural Technology Research Institute Composition for preventing Mycoplasma spp. infection
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
CN104324370B (zh) * 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
US10821165B2 (en) * 2016-01-07 2020-11-03 Universiteit Gent Vaccine strains of brachyspira hyodysenteriae
EP3432921A1 (en) * 2016-03-23 2019-01-30 Intervet International B.V. A combination vaccine against pcv2 and prrs virus infection comprising albumin
CN106497850B (zh) * 2016-12-20 2019-10-29 天津瑞普生物技术股份有限公司 一种纯化猪肺炎支原体的方法
RU2761453C2 (ru) 2016-12-23 2021-12-08 Интервет Интернэшнл Б.В. Комбинированная вакцина для свиней
WO2019121916A1 (en) * 2017-12-22 2019-06-27 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
JP2022536410A (ja) 2019-06-10 2022-08-16 エランコ・ユーエス・インコーポレイテッド Ｍｙｃｏｐｌａｓｍａ培地製剤
WO2021018806A1 (en) * 2019-07-26 2021-02-04 Ceva Sante Animale Igg-depleted porcine serum and the uses thereof
JP2023535066A (ja) 2020-07-24 2023-08-15 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 組合せブタワクチン
KR20220168097A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168102A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168101A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168100A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168099A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168098A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
CN114134098A (zh) * 2021-12-15 2022-03-04 成都史纪生物制药有限公司 一种猪肺炎支原体的灭活方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
WO1987005738A1 (en) 1986-03-13 1987-09-24 Zahnradfabrik Friedrichshafen Ag System for irradiating liquids with radioactive beams
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ZA881694B (en) 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
AU626271B2 (en) 1987-11-03 1992-07-30 Syntex (U.S.A.) Inc. Vaccine adjuvant
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
ATE160699T1 (de) 1990-05-29 1997-12-15 American Cyanamid Co Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
UA27788C2 (uk) 1991-06-06 2000-10-16 Стіхтінг Сентрал Діргенескюндіг Інстітют Композиція, що містить виділений фактор лелістада, вакцинна композиція для вакцинації тварин (варіанти), діагностичний набір для виявлення антитіла
ES2065303T5 (es) 1991-08-26 2001-05-01 Univ Minnesota Procedimiento de diagnosis y vacuna especifica.
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
ATE234916T1 (de) 1991-11-15 2003-04-15 Pfizer Methode zur herstellung von gram-negativen bakteriellen vakzinen
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
AU711350B2 (en) 1994-05-10 1999-10-14 Zoetis Services Llc Improved modified live BRSV vaccine
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) * 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
AU1535299A (en) 1997-11-26 1999-06-15 Iowa State University Research Foundation Inc. Recombinant (mycoplasma hyopneumoniae) vaccine
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
NZ501264A (en) 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
DK1474067T4 (en) 2001-07-02 2017-10-16 Zoetis Services Llc One-dose vaccination with I Mycoplasma Hyopneumoniae / I
EP1521592A2 (en) * 2001-07-02 2005-04-13 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
AU2003280431A1 (en) 2002-06-28 2004-01-19 Department Of Agriculture For And On Behalf Of The State Of New South Wales Immunogenic mycoplasma hyopneumoniae polypeptides
EP1651265B1 (en) * 2003-07-24 2008-04-23 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
US8449989B2 (en) 2003-10-17 2013-05-28 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
KR20070096019A (ko) 2005-01-13 2007-10-01 베링거잉겔하임베트메디카게엠베하 향상된 ｐｒｒｓ 백신
KR101347503B1 (ko) * 2005-09-09 2014-01-02 인터벳 인터내셔널 비.브이. Ｐｃｖ-2 백신
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
EP3320919B1 (en) 2005-12-29 2020-05-27 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
PL2007419T3 (pl) 2006-04-10 2012-09-28 Intervet Int Bv Szczepionka przeciwko mykoplazmie i PRRSV
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
MX2010005014A (es) 2007-11-06 2010-06-30 Wyeth Llc Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
CA2712006A1 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
KR20130126755A (ko) 2008-10-16 2013-11-20 화이자 인코포레이티드 토크 테노 바이러스(ｔｔｖ) 분리물 및 조성물
PL2569007T3 (pl) 2010-05-11 2016-04-29 Intervet Int Bv Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
BR112013004594B1 (pt) 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
MX362166B (es) 2012-03-07 2018-12-14 Ceva Sante Animale Nueva vacuna veterinaria.
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
JP6386999B2 (ja) * 2012-05-17 2018-09-05 ゾエティス・エルエルシー ブタ生殖および呼吸症候群（ｐｒｒｓ）ウイルスに対する離乳前の効果的なワクチン接種

Also Published As

Publication number Publication date
AU2013243535B2 (en) 2017-10-19
BR112014024533A2 (pt) 2017-08-08
CY1124982T1 (el) 2023-01-05
HUE058321T2 (hu) 2022-07-28
RU2014140107A (ru) 2016-05-27
JP2015512448A (ja) 2015-04-27
US11141472B2 (en) 2021-10-12
WO2013152081A1 (en) 2013-10-10
CA2869603C (en) 2018-06-12
KR20150003257A (ko) 2015-01-08
PT2833908T (pt) 2022-02-17
CN104271154A (zh) 2015-01-07
US9120859B2 (en) 2015-09-01
US20170209560A1 (en) 2017-07-27
EP2833908A1 (en) 2015-02-11
AR090611A1 (es) 2014-11-26
KR101747507B1 (ko) 2017-06-14
NI201400117A (es) 2015-03-05
AU2013243535A1 (en) 2014-10-09
MX336504B (es) 2016-01-21
EP2833908B1 (en) 2022-01-05
US9650600B2 (en) 2017-05-16
GT201400210A (es) 2015-06-02
JP6271502B2 (ja) 2018-01-31
SI2833908T1 (sl) 2022-04-29
US10668139B2 (en) 2020-06-02
US20130266601A1 (en) 2013-10-10
US20190134176A1 (en) 2019-05-09
LT2833908T (lt) 2022-02-25
MX2014012014A (es) 2014-11-10
PH12014502250B1 (en) 2014-12-15
US10206991B2 (en) 2019-02-19
HRP20220175T1 (hr) 2022-04-29
US20150284677A1 (en) 2015-10-08
ES2905302T3 (es) 2022-04-07
CL2014002674A1 (es) 2014-12-12
CR20140436A (es) 2014-11-12
AU2013243535C1 (en) 2018-03-01
PH12014502250A1 (en) 2014-12-15
PL2833908T3 (pl) 2022-03-21
MX354756B (es) 2018-03-20
TWI602575B (zh) 2017-10-21
MY166792A (en) 2018-07-23
EP4039271A1 (en) 2022-08-10
TW201345550A (zh) 2013-11-16
DK2833908T3 (da) 2022-02-07
RS62881B1 (sr) 2022-03-31
US20200330577A1 (en) 2020-10-22
HK1207284A1 (en) 2016-01-29
RU2644254C2 (ru) 2018-02-08
HRP20140957A2 (hr) 2015-02-27
CO7160026A2 (es) 2015-01-15
BR112014024533B1 (pt) 2021-06-01
CA2869603A1 (en) 2013-10-10
CN104271154B (zh) 2018-09-04

Similar Documents

Publication Publication Date Title
UA114502C2 (uk) Вакцина mycoplasma hyopneumoniae
UA114503C2 (uk) Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
CO2018004321A2 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
BR112018006350A2 (pt) anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo
EA201790239A1 (ru) Молекула-носитель для антигенов
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
MX2011009437A (es) Vacunas contra cancer a base de de celulas presentadoras de antigeno.
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
BR112013000345A2 (pt) composições antigênicas para vírus sincicial respiratório e métodos
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
EA201400914A1 (ru) Ротавирусная субъединичная вакцина и способы ее получения и применения
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
EA201500700A1 (ru) Иммуногенная композиция, содержащая антигены микоплазм
BR112014026812A8 (pt) Antígenos e combinações de antígenos
EA201390735A1 (ru) Композиции вакцин с фрагментами расщепленных иммуноглобулинов
MX2016009952A (es) Proteinas y antigenos del virus de diarrea epidemica porcino (pedv).
EA201591933A1 (ru) Композиция с пониженной иммуногенностью
TH159867A (th) วัคซีนการรวมของ pcv/ ไมโคพลาสมา ไฮโอพนิวโมนิเอ (mycoplasma hyopneumoniae)
ECSP18039827A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
TH159844A (th) วัคซีนของวัคซีนของไมโคพลาสมา ไฮโอพนิวโมนิเอ (mycoplasma hyopneumoniae)